Date d'enregistrement: December 06 2018

Duration: 36 minutes 29 seconds

The introduction of USP<232> and ICH Q3D requires the pharmaceutical industry to re-evaluate how elemental impurity (heavy metal) testing is performed.  ICP-MS is often used for this type of analysis, but requires a high level of user expertise and can be time-consuming.  USP <735> and EP 2.2.37 enable the use of X-ray fluorescence (XRF) spectrometry as an alternative technology for pharmaceutical elemental impurity testing.  In this webinar, the capabilities of the Epsilon 4 benchtop system set up with our unique calibration solution to analyze elemental impurities according to current regulatory requirements, will be demonstrated.
Table of contents
1. Welcome
01:03
2. Poll Questions
00:00
3. Introduction
01:19
4. Poll Answers
00:00
5. Content of this webinar
00:34
6. USP chapters <232/233>
01:14
7. Elemental impurities in pharmaceutical drugs
01:42
8. ICH Q3D
00:15
9. ICH Q3D
01:21
10. ICH Q3D
01:39
11. Elemental impurity control by ICP
02:18
12. USP chapters <232/233>
00:32
13. X-ray fluorescence spectrometry
01:10
14. Current Analysis
02:33
15. Advantages of XRF
01:39
16. Developments in EDXRF
01:50
17. Epsilon 4
01:30
18. Easy installation
00:23
19. Pharmaceutical standards
01:58
20. Sample preparation
00:49
21. Easy measurement procedure
00:27
22. Application set up
01:25
23. Limit of Quantification for Group 1, 2A & 2B
02:02
24. Accuracy
01:11
25. Accuracy
00:35
26. Accuracy
00:18
27. Enhanced software options for pharmaceutical industry
01:35
28. Summary
00:54
29. Summary
01:06
30. Thank you for your interest
03:07